Mallinckrodt (MNK) Valuation Range, Estimates Cut at Wells Fargo on Methyphenidate ER Issue
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Wells Fargo analyst David Maris lowered his valuation range on Mallinckrodt plc (NYSE: MNK) from $88-$89 to $83-$84 after the the FDA announced a proposal to withdraw approval of an ANDA for methylphenidate hydrochloride (HCl) extended-release (ER) tablets.
The firm lowered Q4 estimate by $0.04 from $1.90 to $1.86 based on the assumption MNK's generic methylphenidate ER is pulled from the market this quarter. In addition, they reduced 2017 estimate by $0.50 from $8.25 to $7.75.
The firm maintained an Outperform rating.
Shares of Mallinckrodt plc closed at $64.96 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wedbush Raises Price Target on Citizens Financial Group (CFG) Following 3Q EPS Beat
- Buffalo Wild Wings (BWLD): Cutting PT On Expected Guide Down - Wells Fargo
- BMO Capital Remains Cautious on Bristol-Myers Squibb (BMY) Despite Decline; PT Lowered to $56
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change
Related EntitiesWells Fargo, David Maris
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!